FY2024 EPS Estimates for TG Therapeutics Cut by B. Riley

TG Therapeutics, Inc. (NASDAQ:TGTX) – Analysts at B. Riley decreased their FY2024 earnings per share estimates for TG Therapeutics in a research report issued on Monday, November 4th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will post earnings of $0.04 per share for the year, down from their previous forecast of $0.05. B. Riley currently has a “Buy” rating and a $34.00 target price on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.13 per share. B. Riley also issued estimates for TG Therapeutics’ Q4 2024 earnings at $0.06 EPS and FY2025 earnings at $0.94 EPS.

Several other research analysts also recently weighed in on the company. The Goldman Sachs Group upped their price target on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday. HC Wainwright upped their price target on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, TD Cowen initiated coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target for the company. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

TG Therapeutics Trading Up 6.2 %

TGTX stock opened at $25.86 on Wednesday. TG Therapeutics has a 1-year low of $9.81 and a 1-year high of $26.99. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The company has a market capitalization of $4.00 billion, a price-to-earnings ratio of -258.00 and a beta of 2.19. The business has a 50 day simple moving average of $23.51 and a two-hundred day simple moving average of $20.17.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The business had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. During the same quarter in the previous year, the company earned $0.73 earnings per share. The company’s revenue for the quarter was down 49.4% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. NBC Securities Inc. boosted its position in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 485 shares during the last quarter. Quarry LP raised its holdings in TG Therapeutics by 9.1% during the 2nd quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 503 shares during the period. Private Advisor Group LLC raised its holdings in TG Therapeutics by 3.9% during the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock valued at $337,000 after buying an additional 542 shares during the period. Blue Trust Inc. raised its holdings in TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 849 shares during the period. Finally, Swiss National Bank raised its holdings in TG Therapeutics by 0.5% during the 1st quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company’s stock valued at $4,321,000 after buying an additional 1,500 shares during the period. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.